Corporate Partners

BeiGene logo

BeiGene Ltd.

Zymeworks granted BeiGene an exclusive license for the research, development and commercialization of ZW25 and ZW49 in Asia and also entered into a collaboration and licensing agreement with BeiGene to develop three bispecific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric and EFECT platform.

 

Leo Pharma A/S logo

Leo Pharma A/S

Collaboration and licensing agreement with Leo Pharma to develop bispecific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric and EFECT platform. Under the terms of the agreement, Zymeworks and Leo are collaborating on the research and development on two bispecific antibodies. Zymeworks will retain rights to develop antibodies resulting from this collaboration in all other therapeutic areas.

 

Johnson & Johnson Innovation & Janssen Biotech, Inc.

Collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the research, development, and commercialization of next generation up to six bispecific antibody therapeutics enabled using Zymeworks' Azymetric™ and EFECT™ platforms. Janssen also has the option to develop two additional bispecific programs under the agreement subject to a future option payment.

 

Daiichi Sankyo

Zymeworks and Daiichi Sankyo began working together in September 2016 through an agreement to develop one bispecific antibody therapeutic. Additionally, Zymeworks obtained a license to certain immuno-oncology antibodies from Daiichi Sankyo, with the right to research, develop, and commercialize multiple bispecific products globally.

In 2018, Daiichi Sankyo entered in a second agreement with Zymeworks and acquired licenses to Zymeworks’ Azymetric™ and EFECT™ technology platforms to develop two additional bispecific antibody therapeutics.

 

GlaxoSmithKline

Collaboration and license agreement with GlaxoSmithKline (GSK) for the research, development, and commercialization of novel Fc-engineered monoclonal and bispecific antibody therapeutics which have been optimized for specific therapeutic effects. Under the agreement, Zymeworks and GSK are collaborating to further develop Zymeworks’ Effector Function Enhancement and Control Technology (EFECT™) platform through the design, engineering, and testing of novel engineered Fc domains tailored to induce specific antibody-mediated immune responses. Both GSK and Zymeworks will have the right to develop and commercialize therapeutic antibody candidates incorporating Zymeworks’ optimized immune-modulating Fc domains.

License agreement with GSK for the research, development, and commercialization of novel bispecific antibodies enabled using Zymeworks' Azymetric™ platform. Under the agreement, GSK will have the option to develop and commercialize multiple bispecific drugs across different disease areas. As part of this second agreement, GSK has gained the right to combined the Azymetric™ platform with novel engineered Fc domains developed under the previously announced collaboration.

 

Celgene Corp.

Collaboration and licensing agreement with Celgene Corp. to develop bispecific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric™ platform. Under the terms of the agreement, Zymeworks and Celgene are collaborating on the research and development on up to 10 bispecific antibodies.

 

Eli Lilly & Co.

Collaboration with Eli Lilly and Company to develop bispecific antibodies, using Zymeworks’ proprietary Azymetric™ platform, against multiple Lilly targets for immunotherapy and other applications, under the terms of the original (2011) and the expanded agreement (2013).

 

Merck & Co.

Collaboration with Merck to develop bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform, toward certain therapeutic targets, under the terms of the original agreement (2011) and the expanded collaboration (2014).